Impact of COVID-19 Outbreak on Neuraminidase Inhibitor, Global Market Research Report 2020

July 2020 | 95 pages | ID: ICDDC0EF4F21EN
QYResearch

Abstracts

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Neuraminidase Inhibitor market in 2020.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyzes the impact of Coronavirus COVID-19 on the Neuraminidase Inhibitor industry.

Segment by Type, the Neuraminidase Inhibitor market is segmented into

• Zanamivir
• Oseltamivir
• Peramivir
• Laninamivir

Segment by Application

• Hospital Pharmacies
• Drug Stores
• Retail Stores
• Others

Global Neuraminidase Inhibitor Market: Regional Analysis
The Neuraminidase Inhibitor market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Neuraminidase Inhibitor market report are:

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Asia-Pacific
• China
• Japan
• South Korea
• India
• Australia
• Taiwan
• Indonesia
• Thailand
• Malaysia
• Philippines
• Vietnam
• Latin America
• Mexico
• Brazil
• Argentina
• Middle East & Africa
• Turkey
• Saudi Arabia
• U.A.E

Global Neuraminidase Inhibitor Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Neuraminidase Inhibitor market include:

• GlaxoSmithKline
• Gilead Sciences
• F. Hoffman-La Roche
• BioCryst
• Daiichi Sankyo

Contents

1 NEURAMINIDASE INHIBITOR MARKET OVERVIEW

1.1 Product Overview and Scope of Neuraminidase Inhibitor
1.2 Covid-19 Impact on Neuraminidase Inhibitor Segment by Type
  1.2.1 Global Neuraminidase Inhibitor Sales Growth Rate Comparison by Type (2021-2026)
  1.2.2 Zanamivir
  1.2.3 Oseltamivir
  1.2.4 Peramivir
  1.2.5 Laninamivir
1.3 Covid-19 Impact on Neuraminidase Inhibitor Segment by Application
  1.3.1 Neuraminidase Inhibitor Sales Comparison by Application: 2020 VS 2026
  1.3.2 Hospital Pharmacies
  1.3.3 Drug Stores
  1.3.4 Retail Stores
  1.3.5 Others
1.4 Covid-19 Impact on Global Neuraminidase Inhibitor Market Size Estimates and Forecasts
  1.4.1 Global Neuraminidase Inhibitor Revenue 2015-2026
  1.4.2 Global Neuraminidase Inhibitor Sales 2015-2026
  1.4.3 Neuraminidase Inhibitor Market Size by Region: 2020 Versus 2026
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
  1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
  1.5.2 Covid-19 Impact: Commodity Prices Indices
  1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Neuraminidase Inhibitor Industry
1.7 COVID-19 Impact: Neuraminidase Inhibitor Market Trends

2 COVID-19 IMPACT ON GLOBAL NEURAMINIDASE INHIBITOR MARKET COMPETITION BY MANUFACTURERS

2.1 Global Neuraminidase Inhibitor Sales Market Share by Manufacturers (2015-2020)
2.2 Global Neuraminidase Inhibitor Revenue Share by Manufacturers (2015-2020)
2.3 Global Neuraminidase Inhibitor Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Neuraminidase Inhibitor Manufacturing Sites, Area Served, Product Type
2.5 Neuraminidase Inhibitor Market Competitive Situation and Trends
  2.5.1 Neuraminidase Inhibitor Market Concentration Rate
  2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
  2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Neuraminidase Inhibitor Players (Opinion Leaders)

3 COVID-19 IMPACT ON NEURAMINIDASE INHIBITOR RETROSPECTIVE MARKET SCENARIO BY REGION

3.1 Global Neuraminidase Inhibitor Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Neuraminidase Inhibitor Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Neuraminidase Inhibitor Market Facts & Figures by Country
  3.3.1 North America Neuraminidase Inhibitor Sales by Country
  3.3.2 North America Neuraminidase Inhibitor Sales by Country
  3.3.3 U.S.
  3.3.4 Canada
3.4 Europe Neuraminidase Inhibitor Market Facts & Figures by Country
  3.4.1 Europe Neuraminidase Inhibitor Sales by Country
  3.4.2 Europe Neuraminidase Inhibitor Sales by Country
  3.4.3 Germany
  3.4.4 France
  3.4.5 U.K.
  3.4.6 Italy
  3.4.7 Russia
3.5 Asia Pacific Neuraminidase Inhibitor Market Facts & Figures by Region
  3.5.1 Asia Pacific Neuraminidase Inhibitor Sales by Region
  3.5.2 Asia Pacific Neuraminidase Inhibitor Sales by Region
  3.5.3 China
  3.5.4 Japan
  3.5.5 South Korea
  3.5.6 India
  3.5.7 Australia
  3.5.8 Taiwan
  3.5.9 Indonesia
  3.5.10 Thailand
  3.5.11 Malaysia
  3.5.12 Philippines
  3.5.13 Vietnam
3.6 Latin America Neuraminidase Inhibitor Market Facts & Figures by Country
  3.6.1 Latin America Neuraminidase Inhibitor Sales by Country
  3.6.2 Latin America Neuraminidase Inhibitor Sales by Country
  3.6.3 Mexico
  3.6.3 Brazil
  3.6.3 Argentina
3.7 Middle East and Africa Neuraminidase Inhibitor Market Facts & Figures by Country
  3.7.1 Middle East and Africa Neuraminidase Inhibitor Sales by Country
  3.7.2 Middle East and Africa Neuraminidase Inhibitor Sales by Country
  3.7.3 Turkey
  3.7.4 Saudi Arabia
  3.7.5 U.A.E

4 COVID-19 IMPACT ON GLOBAL NEURAMINIDASE INHIBITOR HISTORIC MARKET ANALYSIS BY TYPE

4.1 Global Neuraminidase Inhibitor Sales Market Share by Type (2015-2020)
4.2 Global Neuraminidase Inhibitor Revenue Market Share by Type (2015-2020)
4.3 Global Neuraminidase Inhibitor Price Market Share by Type (2015-2020)
4.4 Global Neuraminidase Inhibitor Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 COVID-19 IMPACT ON GLOBAL NEURAMINIDASE INHIBITOR HISTORIC MARKET ANALYSIS BY APPLICATION

5.1 Global Neuraminidase Inhibitor Sales Market Share by Application (2015-2020)
5.2 Global Neuraminidase Inhibitor Revenue Market Share by Application (2015-2020)
5.3 Global Neuraminidase Inhibitor Price by Application (2015-2020)

6 COMPANY PROFILES AND KEY FIGURES IN NEURAMINIDASE INHIBITOR BUSINESS

6.1 GlaxoSmithKline
  6.1.1 Corporation Information
  6.1.2 GlaxoSmithKline Description, Business Overview and Total Revenue
  6.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  6.1.4 GlaxoSmithKline Products Offered
  6.1.5 GlaxoSmithKline Recent Development and Response to COVID-19
6.2 Gilead Sciences
  6.2.1 Gilead Sciences Corporation Information
  6.2.2 Gilead Sciences Description, Business Overview and Total Revenue
  6.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  6.2.4 Gilead Sciences Products Offered
  6.2.5 Gilead Sciences Recent Development and Response to COVID-19
6.3 F. Hoffman-La Roche
  6.3.1 F. Hoffman-La Roche Corporation Information
  6.3.2 F. Hoffman-La Roche Description, Business Overview and Total Revenue
  6.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  6.3.4 F. Hoffman-La Roche Products Offered
  6.3.5 F. Hoffman-La Roche Recent Development and Response to COVID-19
6.4 BioCryst
  6.4.1 BioCryst Corporation Information
  6.4.2 BioCryst Description, Business Overview and Total Revenue
  6.4.3 BioCryst Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  6.4.4 BioCryst Products Offered
  6.4.5 BioCryst Recent Development and Response to COVID-19
6.5 Daiichi Sankyo
  6.5.1 Daiichi Sankyo Corporation Information
  6.5.2 Daiichi Sankyo Description, Business Overview and Total Revenue
  6.5.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2015-2020)
  6.5.4 Daiichi Sankyo Products Offered
  6.5.5 Daiichi Sankyo Recent Development and Response to COVID-19

7 NEURAMINIDASE INHIBITOR MANUFACTURING COST ANALYSIS

7.1 Neuraminidase Inhibitor Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Key Raw Materials Price Trend
  7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Neuraminidase Inhibitor
7.4 Neuraminidase Inhibitor Industrial Chain Analysis

8 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS

8.1 Marketing Channel
8.2 Neuraminidase Inhibitor Distributors List
8.3 Neuraminidase Inhibitor Customers

9 MARKET DYNAMICS

9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis

10 GLOBAL MARKET FORECAST

10.1 Global Neuraminidase Inhibitor Market Estimates and Projections by Type
  10.1.1 Global Forecasted Sales of Neuraminidase Inhibitor by Type (2021-2026)
  10.1.2 Global Forecasted Revenue of Neuraminidase Inhibitor by Type (2021-2026)
10.2 Neuraminidase Inhibitor Market Estimates and Projections by Application
  10.2.1 Global Forecasted Sales of Neuraminidase Inhibitor by Application (2021-2026)
  10.2.2 Global Forecasted Revenue of Neuraminidase Inhibitor by Application (2021-2026)
10.3 Neuraminidase Inhibitor Market Estimates and Projections by Region
  10.3.1 Global Forecasted Sales of Neuraminidase Inhibitor by Region (2021-2026)
  10.3.2 Global Forecasted Revenue of Neuraminidase Inhibitor by Region (2021-2026)
10.4 North America Neuraminidase Inhibitor Estimates and Projections (2021-2026)
10.5 Europe Neuraminidase Inhibitor Estimates and Projections (2021-2026)
10.6 Asia Pacific Neuraminidase Inhibitor Estimates and Projections (2021-2026)
10.7 Latin America Neuraminidase Inhibitor Estimates and Projections (2021-2026)
10.8 Middle East and Africa Neuraminidase Inhibitor Estimates and Projections (2021-2026)

11 RESEARCH FINDING AND CONCLUSION

12 METHODOLOGY AND DATA SOURCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Neuraminidase Inhibitor Sales (K Units) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Neuraminidase Inhibitor Sales (K Units) Comparison by Application: 2020 VS 2026
Table 3. Global Neuraminidase Inhibitor Market Size by Type (K Units) (US$ Million) (2020 VS 2026)
Table 4. COVID-19 Impact Global Market: (Four Neuraminidase Inhibitor Market Size Forecast Scenarios)
Table 5. Opportunities and Trends for Neuraminidase Inhibitor Players in the COVID-19 Landscape
Table 6. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 7. Key Regions/Countries Measures against Covid-19 Impact
Table 8. Proposal for Neuraminidase Inhibitor Players to Combat Covid-19 Impact
Table 9. Global Key Neuraminidase Inhibitor Manufacturers Covered in This Study
Table 10. Global Neuraminidase Inhibitor Sales (K Units) by Manufacturers (2015-2020)
Table 11. Global Neuraminidase Inhibitor Sales Share by Manufacturers (2015-2020)
Table 12. Global Neuraminidase Inhibitor Revenue (Million USD) by Manufacturers (2015-2020)
Table 13. Global Neuraminidase Inhibitor Revenue Share by Manufacturers (2015-2020)
Table 14. Global Market Neuraminidase Inhibitor Average Price (US$/Unit) of Key Manufacturers (2015-2020)
Table 15. Manufacturers Neuraminidase Inhibitor Sales Sites and Area Served
Table 16. Manufacturers Neuraminidase Inhibitor Product Types
Table 17. Global Neuraminidase Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 18. Global Neuraminidase Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuraminidase Inhibitor as of 2019)
Table 19.Manufacturers Mergers & Acquisitions, Expansion Plans
Table 20. Main Points Interviewed from Key Neuraminidase Inhibitor Players
Table 21. Global Neuraminidase Inhibitor Sales (K Units) by Region (2015-2020)
Table 22. Global Neuraminidase Inhibitor Sales Market Share by Region (2015-2020)
Table 23. Global Neuraminidase Inhibitor Revenue (Million US$) by Region (2015-2020)
Table 24. Global Neuraminidase Inhibitor Revenue Market Share by Region (2015-2020)
Table 25. North America Neuraminidase Inhibitor Sales by Country (2015-2020) (K Units)
Table 26. North America Neuraminidase Inhibitor Sales Market Share by Country (2015-2020)
Table 27. North America Neuraminidase Inhibitor Revenue by Country (2015-2020) (US$ Million)
Table 28. North America Neuraminidase Inhibitor Revenue Market Share by Country (2015-2020)
Table 29. Europe Neuraminidase Inhibitor Sales by Country (2015-2020) (K Units)
Table 30. Europe Neuraminidase Inhibitor Sales Market Share by Country (2015-2020)
Table 31. Europe Neuraminidase Inhibitor Revenue by Country (2015-2020) (US$ Million)
Table 32. Europe Neuraminidase Inhibitor Revenue Market Share by Country (2015-2020)
Table 33. Asia Pacific Neuraminidase Inhibitor Sales by Region (2015-2020) (K Units)
Table 34. Asia Pacific Neuraminidase Inhibitor Sales Market Share by Region (2015-2020)
Table 35. Asia Pacific Neuraminidase Inhibitor Revenue by Region (2015-2020) (US$ Million)
Table 36. Asia Pacific Neuraminidase Inhibitor Revenue Market Share by Region (2015-2020)
Table 37. Latin America Neuraminidase Inhibitor Sales by Country (2015-2020) (K Units)
Table 38. Latin America Neuraminidase Inhibitor Sales Market Share by Country (2015-2020)
Table 39. Latin America Neuraminidase Inhibitor Revenue by Country (2015-2020) (US$ Million)
Table 40. Latin America Neuraminidase Inhibitor Revenue Market Share by Country (2015-2020)
Table 41. Middle East and Africa Neuraminidase Inhibitor Sales by Country (2015-2020) (K Units)
Table 42. Middle East and Africa Neuraminidase Inhibitor Sales Market Share by Country (2015-2020)
Table 43. Middle East and Africa Neuraminidase Inhibitor Revenue by Country (2015-2020) (US$ Million)
Table 44. Middle East and Africa Neuraminidase Inhibitor Revenue Market Share by Country (2015-2020)
Table 45. Global Neuraminidase Inhibitor Sales (K Units) by Type (2015-2020)
Table 46. Global Neuraminidase Inhibitor Sales Share by Type (2015-2020)
Table 47. Global Neuraminidase Inhibitor Revenue (Million US$) by Type (2015-2020)
Table 48. Global Neuraminidase Inhibitor Revenue Share by Type (2015-2020)
Table 49. Global Neuraminidase Inhibitor Price (US$/Unit) by Type (2015-2020)
Table 50. Global Neuraminidase Inhibitor Sales (K Units) by Application (2015-2020)
Table 51. Global Neuraminidase Inhibitor Sales Market Share by Application (2015-2020)
Table 52. Global Neuraminidase Inhibitor Sales Growth Rate by Application (2015-2020)
Table 53. GlaxoSmithKline Neuraminidase Inhibitor Corporation Information
Table 54. GlaxoSmithKline Description and Business Overview
Table 55. GlaxoSmithKline Neuraminidase Inhibitor Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 56. GlaxoSmithKline Main Product
Table 57. GlaxoSmithKline Recent Development
Table 58. Gilead Sciences Neuraminidase Inhibitor Corporation Information
Table 59. Gilead Sciences Corporation Information
Table 60. Gilead Sciences Neuraminidase Inhibitor Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 61. Gilead Sciences Main Product
Table 62. Gilead Sciences Recent Development
Table 63. F. Hoffman-La Roche Neuraminidase Inhibitor Corporation Information
Table 64. F. Hoffman-La Roche Corporation Information
Table 65. F. Hoffman-La Roche Neuraminidase Inhibitor Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 66. F. Hoffman-La Roche Main Product
Table 67. F. Hoffman-La Roche Recent Development
Table 68. BioCryst Neuraminidase Inhibitor Corporation Information
Table 69. BioCryst Corporation Information
Table 70. BioCryst Neuraminidase Inhibitor Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 71. BioCryst Main Product
Table 72. BioCryst Recent Development
Table 73. Daiichi Sankyo Neuraminidase Inhibitor Corporation Information
Table 74. Daiichi Sankyo Corporation Information
Table 75. Daiichi Sankyo Neuraminidase Inhibitor Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 76. Daiichi Sankyo Main Product
Table 77. Daiichi Sankyo Recent Development
Table 78. Sales Base and Market Concentration Rate of Raw Material
Table 79. Key Suppliers of Raw Materials
Table 80. Neuraminidase Inhibitor Distributors List
Table 81. Neuraminidase Inhibitor Customers List
Table 82. Market Key Trends
Table 83. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 84. Key Challenges
Table 85. Global Neuraminidase Inhibitor Sales (K Units) Forecast by Type (2021-2026)
Table 86. Global Neuraminidase Inhibitor Sales Market Share Forecast by Type (2021-2026)
Table 87. Global Neuraminidase Inhibitor Revenue (Million US$) Forecast by Type (2021-2026)
Table 88. Global Neuraminidase Inhibitor Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 89. Global Neuraminidase Inhibitor Sales (K Units) Forecast by Application (2021-2026)
Table 90. Global Neuraminidase Inhibitor Revenue (Million US$) Forecast by Application (2021-2026)
Table 91. Global Neuraminidase Inhibitor Sales (K Units) Forecast by Region (2021-2026)
Table 92. Global Neuraminidase Inhibitor Sales Market Share Forecast by Region (2021-2026)
Table 93. Global Neuraminidase Inhibitor Revenue Forecast by Region (2021-2026) (US$ Million)
Table 94. Global Neuraminidase Inhibitor Revenue Market Share Forecast by Region (2021-2026)
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Neuraminidase Inhibitor
Figure 2. Global Neuraminidase Inhibitor Sales Market Share by Type: 2020 VS 2026
Figure 3. Zanamivir Product Picture
Figure 4. Oseltamivir Product Picture
Figure 5. Peramivir Product Picture
Figure 6. Laninamivir Product Picture
Figure 7. Global Neuraminidase Inhibitor Consumption Market Share by Application: 2020 VS 2026
Figure 8. Hospital Pharmacies
Figure 9. Drug Stores
Figure 10. Retail Stores
Figure 11. Others
Figure 12. Global Neuraminidase Inhibitor Market Size 2015-2026 (US$ Million)
Figure 13. Global Neuraminidase Inhibitor Sales Capacity (K Units) (2015-2026)
Figure 14. Global Neuraminidase Inhibitor Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Neuraminidase Inhibitor Sales Share by Manufacturers in 2020
Figure 16. Global Neuraminidase Inhibitor Revenue Share by Manufacturers in 2019
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neuraminidase Inhibitor Revenue in 2019
Figure 18. Neuraminidase Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 19. Global Neuraminidase Inhibitor Sales Market Share by Region (2015-2020)
Figure 20. Global Neuraminidase Inhibitor Sales Market Share by Region in 2019
Figure 21. Global Neuraminidase Inhibitor Revenue Market Share by Region (2015-2020)
Figure 22. Global Neuraminidase Inhibitor Revenue Market Share by Region in 2019
Figure 23. North America Neuraminidase Inhibitor Sales Market Share by Country in 2019
Figure 24. North America Neuraminidase Inhibitor Revenue Market Share by Country in 2019
Figure 25. U.S. Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 26. U.S. Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 27. Canada Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 28. Canada Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 29. Europe Neuraminidase Inhibitor Sales Market Share by Country in 2019
Figure 30. Europe Neuraminidase Inhibitor Revenue Market Share by Country in 2019
Figure 31. Germany Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 32. Germany Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 33. France Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 34. France Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. U.K. Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.K. Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Italy Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 38. Italy Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Russia Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 40. Russia Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. Asia Pacific Neuraminidase Inhibitor Sales Market Share by Region in 2019
Figure 42. Asia Pacific Neuraminidase Inhibitor Revenue Market Share by Region in 2019
Figure 43. China Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 44. China Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. Japan Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 46. Japan Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. South Korea Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 48. South Korea Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. India Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 50. India Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Australia Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 52. Australia Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Taiwan Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 54. Taiwan Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Indonesia Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 56. Indonesia Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Thailand Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 58. Thailand Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Malaysia Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 60. Malaysia Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Philippines Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 62. Philippines Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Vietnam Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 64. Vietnam Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Latin America Neuraminidase Inhibitor Sales Market Share by Country in 2019
Figure 66. Latin America Neuraminidase Inhibitor Revenue Market Share by Country in 2019
Figure 67. Mexico Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 68. Mexico Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Brazil Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 70. Brazil Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Argentina Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 72. Argentina Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Middle East and Africa Neuraminidase Inhibitor Sales Market Share by Country in 2019
Figure 74. Middle East and Africa Neuraminidase Inhibitor Revenue Market Share by Country in 2019
Figure 75. Turkey Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 76. Turkey Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Saudi Arabia Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 78. Saudi Arabia Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. U.A.E Neuraminidase Inhibitor Sales Growth Rate (2015-2020) (K Units)
Figure 80. U.A.E Neuraminidase Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Sales Market Share of Neuraminidase Inhibitor by Type (2015-2020)
Figure 82. Sales Market Share of Neuraminidase Inhibitor by Type in 2019
Figure 83. Revenue Share of Neuraminidase Inhibitor by Type (2015-2020)
Figure 84. Revenue Market Share of Neuraminidase Inhibitor by Type in 2019
Figure 85. Global Neuraminidase Inhibitor Sales Growth by Type (2015-2020) (K Units)
Figure 86. Global Neuraminidase Inhibitor Sales Market Share by Application (2015-2020)
Figure 87. Global Neuraminidase Inhibitor Sales Market Share by Application in 2019
Figure 88. Global Revenue Share of Neuraminidase Inhibitor by Application (2015-2020)
Figure 89. Global Revenue Share of Neuraminidase Inhibitor by Application in 2020
Figure 90. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. Gilead Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 92. F. Hoffman-La Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 93. BioCryst Total Revenue (US$ Million): 2019 Compared with 2018
Figure 94. Daiichi Sankyo Total Revenue (US$ Million): 2019 Compared with 2018
Figure 95. Price Trend of Key Raw Materials
Figure 96. Manufacturing Cost Structure of Neuraminidase Inhibitor
Figure 97. Manufacturing Process Analysis of Neuraminidase Inhibitor
Figure 98. Neuraminidase Inhibitor Industrial Chain Analysis
Figure 99. Channels of Distribution
Figure 100. Distributors Profiles
Figure 101. Porter's Five Forces Analysis
Figure 102. North America Neuraminidase Inhibitor Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 103. North America Neuraminidase Inhibitor Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 104. Europe Neuraminidase Inhibitor Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 105. Europe Neuraminidase Inhibitor Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 106. Latin America Neuraminidase Inhibitor Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 107. Latin America Neuraminidase Inhibitor Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 108. Middle East and Africa Neuraminidase Inhibitor Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 109. Middle East and Africa Neuraminidase Inhibitor Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 110. Asia Pacific Neuraminidase Inhibitor Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 111. Asia Pacific Neuraminidase Inhibitor Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 112. Bottom-up and Top-down Approaches for This Report
Figure 113. Data Triangulation
Figure 114. Key Executives Interviewed